AstraZeneca is global innovation-driven biopharmaceutical company specialising in the discovery, development, manufacturing and marketing of prescription medicines that make a meaningful difference in healthcare. AstraZeneca discovers new medicines that are designed to improve the health and quality of life of patients around the world - medicines which are innovative, effective and which offer added benefits such as reduced side effects or better ways of taking the treatment. They also focus on getting the best from every medicine they make by exploring all the ways it can be used or improved. Their business strategy sets out their path to success in delivering great medicines to patients through innovative science and global excellence in development and commercialisation.
TypePublic
HQCambridge, GB
Founded1999
Size (employees)61,100 (est)+3%
Websiteastrazeneca.com
AstraZeneca was founded in 1999 and is headquartered in Cambridge, GB
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at AstraZeneca

Leif Johansson

Leif Johansson

Non-Executive Chairman of the Board
Pascal Soriot

Pascal Soriot

Executive Director and Chief Executive Officer
Marc Dunoyer

Marc Dunoyer

Executive Director and Chief Financial Officer
Rudy Markham

Rudy Markham

Senior Independent Non-Executive Director
Genevieve Berger

Genevieve Berger

Non-Executive Director
Philip Broadley

Philip Broadley

Non-Executive Director
Show more

AstraZeneca Office Locations

AstraZeneca has offices in Seattle, New Haven, Tampa, Jersey and in 166 other locations
Shanghai, CN
43/F CITIC Square, 1168 Nan Jing Xi Road
Wedel, DE
Wedel, Tinsdaler Weg 183
Hong Kong, HK
18/F, Shui On Centre, 6-8 Harbour Road, Wanchai
Bangalore, IN
Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road
Osaka, JP
Grand Front Osaka Tower B, 3-1, Ofuka-cho, Kita-ku
London, GB
15 Stanhope Gate
Show all (171)
Report incorrect company information

AstraZeneca Financials and Metrics

AstraZeneca Revenue

Embed Graph
AstraZeneca's revenue was reported to be £22.46 b in FY, 2017
GBP

Revenue (FY, 2017)

22.5b

Gross profit (FY, 2017)

18.1b

Gross profit margin (FY, 2017), %

80.8%

Net income (FY, 2017)

2.9b

EBITDA (FY, 2017)

6.7b

EBIT (FY, 2017)

3.7b

Market capitalization (15-Oct-2018)

94.9b

Closing stock price (15-Oct-2018)

37.5

Cash (31-Dec-2017)

3.3b

EV

93.9b
AstraZeneca's current market capitalization is $94.9 b.
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

5.4b5.2b5.5b11.4b12.1b11.4b11.1b10.5b11.5b14.0b13.5b14.8b19.8b16.9b19.6b19.1b23.0b22.5b

Revenue growth, %

1%(9%)(10%)

Cost of goods sold

2.2b2.0b2.2b3.7b3.7b3.1b2.8b2.5b2.8b3.1b2.7b3.2b4.1b3.5b4.3b3.6b4.1b4.3b

Gross profit

3.1b3.2b3.4b7.6b8.4b8.3b8.3b8.0b8.7b10.8b10.8b11.6b15.7b13.4b15.3b15.5b18.9b18.1b
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

259.0m303.0m206.0m265.0m683.0m489.0m453.0m409.0m565.0m2.9b3.6b2.9b2.7b6.1b4.7b4.8b5.0b3.3b

Accounts Receivable

935.0m969.0m1.1b1.8b1.8b1.7b1.7b1.8b1.9b2.2b2.2b2.7b3.5b3.6b3.5b3.6b2.6b2.8b

Inventories

681.0m728.0m798.0m1.3b1.4b1.7b1.6b1.7b1.6b1.3b1.2b1.1b1.0b1.3b1.4b1.7b2.3b3.0b

Current Assets

3.0b2.9b2.7b6.1b7.0b6.8b7.6b7.2b7.7b8.0b8.7b8.6b10.0b13.2b12.2b12.3b13.0b12.9b
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

655.0m736.0m715.0m704.0m1.7b2.1b1.8b1.7b2.1b2.8b3.1b2.8b3.8b1.7b913.3m2.2b3.4b2.9b

Cash From Operating Activities

1.1b1.2b1.2b1.9b2.8b2.6b3.5b2.4b3.2b3.9b3.9b3.8b5.5b4.9b5.2b4.0b4.1b3.6b

Dividends Paid

332.0m365.0m399.0m764.0m1.9b850.0m753.0m754.0m833.0m976.0m1.1b1.3b1.7b2.6b2.7b

Cash From Financing Activities

(39.0m)(32.0m)(96.0m)(112.0m)(267.0m)(665.0m)(794.0m)(811.0m)(740.0m)(2.7b)(2.7b)3.0b(4.0b)(2.0b)(2.0b)3.4b(1.3b)(2.9b)
GBPY, 2017

EV/EBITDA

14 x

EV/EBIT

25.5 x

EV/CFO

26.2 x

Revenue/Employee

367.7k

Debt/Equity

0.2 x

Financial Leverage

4.2 x
Show all financial metrics

AstraZeneca Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016

Health Facilities Activated

250 403

Phase I Trials Products

33 24 44 41

Projects in R&D Pipeline

99 133 146 132

Young Health Programme Members

1.40 m1.60 m
Show all operating metrics

AstraZeneca Revenue Breakdown

Embed Graph

AstraZeneca revenue breakdown by business segment: 22.3% from Respiratory, Inflammation and Autoimmunity, 23.8% from Infection, Neuroscience and Gastrointestinal:, 15.9% from Oncology and 38.1% from Cardiovascular and Metabolic Diseases

Report incorrect company information

AstraZeneca Online and Social Media Presence

Embed Graph
Report incorrect company information

AstraZeneca News and Updates

Women’s Health Global Market 2018 Top Key Players – Agile Therapeutics, Allergan , Amgen , AstraZeneca , Bayer AG , Bristol-Myers Squibb Company and Forecast to 2023

Wiseguyreports.Com Added New Market Research Report On -“Women’s Health Market 2018 Key Players, Applications and Future Demand Forecast to 2023 ”. Posted via Industry Today. Follow us on Twitter @IndustryToday

Cough Remedies 2018 Global Market Key Players – Johnson & Johnson, Reckitt Benckiser, Bayer, GlaxoSmithKline, AstraZeneca – Analysis and Forecast to 2023

WiseGuyRerports.com Presents “Global Cough Remedies Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023” New Document to its Studies Database Posted via Industry Today. Follow us on Twitter @IndustryToday

AstraZeneca will keep UK investment freeze if no Brexit clarity

AstraZeneca will keep its freeze on manufacturing investments in Britain if the country's exit from the European Union fails to give enough clarity on future trading relations, the drugmaker's chairman was quoted as saying on Monday.

AstraZeneca halts UK investments due to Brexit - Le Monde

PARIS (Reuters) - AstraZeneca has suspended investments in Britain due to the lack of clarity over the country's departure from the European Union, the pharmaceutical firm's non-executive chairman Leif Johansson told France's Le Monde newspaper.

AstraZeneca halts UK investments due to Brexit uncertainties - Le Monde

AstraZeneca has suspended investments in Britain due to the lack of clarity over the country's departure from the European Union, the pharmaceutical firm's non-executive chairman Leif Johansson told France's Le Monde newspaper.

Novo Nordisk hires AstraZeneca executive to revive struggling biopharma unit

Novo Nordisk is in advanced talks to acquire assets to bolster its struggling biopharma business, its chief executive said on Monday after the drugmaker announced it had hired an AstraZeneca executive to head the unit.
Show more
Report incorrect company information

AstraZeneca Company Life and Culture

Report incorrect company information